Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 179

Similar articles for PubMed (Select 19208827)

1.

Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma.

Lam W, Bussom S, Cheng YC.

Mol Cancer Ther. 2009 Feb;8(2):415-23. doi: 10.1158/1535-7163.MCT-08-0692. Epub 2009 Feb 10.

2.

The impact of hypoxic treatment on the expression of phosphoglycerate kinase and the cytotoxicity of troxacitabine and gemcitabine.

Lam W, Leung CH, Bussom S, Cheng YC.

Mol Pharmacol. 2007 Sep;72(3):536-44. Epub 2007 Jun 12.

4.

Synergistic antitumor activity of troxacitabine and camptothecin in selected human cancer cell lines.

Kim TE, Park SY, Hsu CH, Dutschman GE, Cheng YC.

Mol Pharmacol. 2004 Aug;66(2):285-92.

5.

Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.

Gourdeau H, Clarke ML, Ouellet F, Mowles D, Selner M, Richard A, Lee N, Mackey JR, Young JD, Jolivet J, Lafrenière RG, Cass CE.

Cancer Res. 2001 Oct 1;61(19):7217-24.

7.

Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.

Damaraju VL, Bouffard DY, Wong CK, Clarke ML, Mackey JR, Leblond L, Cass CE, Grey M, Gourdeau H.

BMC Cancer. 2007 Jul 3;7:121.

8.

Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.

Gourdeau H, Genne P, Kadhim S, Bibeau L, Duchamp O, Ouellet F, deMuys JM, Bouffard DY, Attardo G.

Cancer Chemother Pharmacol. 2002 Dec;50(6):490-6. Epub 2002 Oct 16.

PMID:
12451476
9.

Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.

Denlinger CE, Rundall BK, Keller MD, Jones DR.

Ann Thorac Surg. 2004 Oct;78(4):1207-14; discussion 1207-14.

PMID:
15464472
10.

Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.

Bouffard DY, Jolivet J, Leblond L, Hamelin B, Ouellet F, Barbeau S, Richard A, Gourdeau H.

Cancer Chemother Pharmacol. 2003 Dec;52(6):497-506. Epub 2003 Sep 3.

PMID:
12955470
11.

In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.

Radi M, Adema AD, Daft JR, Cho JH, Hoebe EK, Alexander LE, Peters GJ, Chu CK.

J Med Chem. 2007 May 3;50(9):2249-53. Epub 2007 Apr 10.

PMID:
17419604
12.

Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.

Higgins B, Kolinsky K, Smith M, Beck G, Rashed M, Adames V, Linn M, Wheeldon E, Gand L, Birnboeck H, Hoffmann G.

Anticancer Drugs. 2004 Jun;15(5):503-12.

PMID:
15166626
13.

Action of troxacitabine on cells transduced with human cytidine deaminase cDNA.

Boivin AJ, Gourdeau H, Momparler RL.

Cancer Invest. 2004;22(1):25-9.

PMID:
15069761
14.
15.

Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.

Gourdeau H, Leblond L, Hamelin B, Dong K, Ouellet F, Boudreau C, Custeau D, Richard A, Gilbert MJ, Jolivet J.

Clin Cancer Res. 2004 Nov 15;10(22):7692-702.

16.

Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration.

Grove KL, Guo X, Liu SH, Gao Z, Chu CK, Cheng YC.

Cancer Res. 1995 Jul 15;55(14):3008-11.

17.

Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.

Ceresa C, Giovannetti E, Voortman J, Laan AC, Honeywell R, Giaccone G, Peters GJ.

Mol Cancer Ther. 2009 May;8(5):1026-36. doi: 10.1158/1535-7163.MCT-08-0700. Epub 2009 Apr 21.

18.

Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.

Kadhim SA, Bowlin TL, Waud WR, Angers EG, Bibeau L, DeMuys JM, Bednarski K, Cimpoia A, Attardo G.

Cancer Res. 1997 Nov 1;57(21):4803-10.

19.
20.

The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.

Weitman S, Marty J, Jolivet J, Locas C, Von Hoff DD.

Clin Cancer Res. 2000 Apr;6(4):1574-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk